Atea Pharmaceuticals, Inc. (AVIR), a clinical-stage biopharmaceutical company developing oral direct-acting antiviral therapies, is on track to report topline results from its phase II combination program in a hepatitis C virus (HCV) trial early this month.
The hepatitis C virus (HCV) causes Hepatitis C, a liver disease that often presents no symptoms, leading many individuals to remain unaware that they have it. If not treated, hepatitis C can result in serious liver damage, such as scarring (cirrhosis) and potentially liver cancer.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com